Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy

Introduction: Serum platelet-activating factor (PAF) was proven to be associated with gestational hypertension. However, the predictive value of serum PAF at early pregnancy for the occurrence and outcomes of hypertensive disorders complicating pregnancy (HDCP) remained unclear. Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Shasha Liu, Qianyu Lan, Weiling Li, Jiefang Zhang, Liman Fu, Yanlei Xu, Yuan Li
Format: Article
Language:English
Published: Karger Publishers 2025-01-01
Series:Kidney & Blood Pressure Research
Online Access:https://karger.com/article/doi/10.1159/000543242
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850133608311816192
author Shasha Liu
Qianyu Lan
Weiling Li
Jiefang Zhang
Liman Fu
Yanlei Xu
Yuan Li
author_facet Shasha Liu
Qianyu Lan
Weiling Li
Jiefang Zhang
Liman Fu
Yanlei Xu
Yuan Li
author_sort Shasha Liu
collection DOAJ
description Introduction: Serum platelet-activating factor (PAF) was proven to be associated with gestational hypertension. However, the predictive value of serum PAF at early pregnancy for the occurrence and outcomes of hypertensive disorders complicating pregnancy (HDCP) remained unclear. Methods: The demographic and clinical characteristics of patients were compared among the different subgroups. The serum PAF level was determined using an enzyme-linked immunosorbent assay. The predictive value of serum PAF for the occurrence and outcomes of HDCP was evaluated using receiver operating characteristic curve analysis. The correlation of serum PAF with blood pressure was assessed using Spearman analysis. Results: Both systolic blood pressure and diastolic blood pressure were significantly higher in HDCP patients, as well as the serum levels of TNF-α and IL-1β at diagnosis/enrollment, while serum levels of IL-10 showed the opposite trend. Serum PAF levels were significantly higher in patients with HDCP compared to normal pregnant women. Furthermore, serum PAF levels were higher in HDCP patients with mild preeclampsia compared to those with gestational hypertension and even more elevated in HDCP patients with severe preeclampsia at the early pregnancy stage and at diagnosis. In HDCP patients, increased serum PAF levels at early pregnancy and at diagnosis were associated with poor outcomes. Additionally, serum PAF levels could predict the occurrence of HDCP and poor outcomes. Conclusion: Serum PAF from HDCP patients at both the early pregnancy and diagnosis stages could effectively predict the occurrence and outcome of HDCP.
format Article
id doaj-art-b07d49be40e44ee493d80e9d9b1260d7
institution OA Journals
issn 1423-0143
language English
publishDate 2025-01-01
publisher Karger Publishers
record_format Article
series Kidney & Blood Pressure Research
spelling doaj-art-b07d49be40e44ee493d80e9d9b1260d72025-08-20T02:31:55ZengKarger PublishersKidney & Blood Pressure Research1423-01432025-01-0150115116010.1159/000543242Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating PregnancyShasha LiuQianyu LanWeiling LiJiefang ZhangLiman FuYanlei XuYuan Li Introduction: Serum platelet-activating factor (PAF) was proven to be associated with gestational hypertension. However, the predictive value of serum PAF at early pregnancy for the occurrence and outcomes of hypertensive disorders complicating pregnancy (HDCP) remained unclear. Methods: The demographic and clinical characteristics of patients were compared among the different subgroups. The serum PAF level was determined using an enzyme-linked immunosorbent assay. The predictive value of serum PAF for the occurrence and outcomes of HDCP was evaluated using receiver operating characteristic curve analysis. The correlation of serum PAF with blood pressure was assessed using Spearman analysis. Results: Both systolic blood pressure and diastolic blood pressure were significantly higher in HDCP patients, as well as the serum levels of TNF-α and IL-1β at diagnosis/enrollment, while serum levels of IL-10 showed the opposite trend. Serum PAF levels were significantly higher in patients with HDCP compared to normal pregnant women. Furthermore, serum PAF levels were higher in HDCP patients with mild preeclampsia compared to those with gestational hypertension and even more elevated in HDCP patients with severe preeclampsia at the early pregnancy stage and at diagnosis. In HDCP patients, increased serum PAF levels at early pregnancy and at diagnosis were associated with poor outcomes. Additionally, serum PAF levels could predict the occurrence of HDCP and poor outcomes. Conclusion: Serum PAF from HDCP patients at both the early pregnancy and diagnosis stages could effectively predict the occurrence and outcome of HDCP. https://karger.com/article/doi/10.1159/000543242
spellingShingle Shasha Liu
Qianyu Lan
Weiling Li
Jiefang Zhang
Liman Fu
Yanlei Xu
Yuan Li
Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
Kidney & Blood Pressure Research
title Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
title_full Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
title_fullStr Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
title_full_unstemmed Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
title_short Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy
title_sort clinical values of serum platelet activating factor in hypertensive disorders complicating pregnancy
url https://karger.com/article/doi/10.1159/000543242
work_keys_str_mv AT shashaliu clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT qianyulan clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT weilingli clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT jiefangzhang clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT limanfu clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT yanleixu clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy
AT yuanli clinicalvaluesofserumplateletactivatingfactorinhypertensivedisorderscomplicatingpregnancy